

# **EXHIBIT B**

<b>Loss Chart</b>															
Losses of Susan S. Church in Cocrystal Pharma, Inc. f/k/a/ BioZone Pharmaceuticals, Inc. (COCOP)															
Client Name	Susan S. Church	90 Day Lookback Average	\$2.4910	LIFO Loss Total	\$52,204.61										
Company Name	Cocrystal Pharma, Inc. f/k/a/ BioZone Pharmaceuticals, Inc.	Dura LIFO Total	\$52,204.61												
Ticker Symbol	COCOP	Shares Retained	4,333												
Class Period Start	9/23/2013														
Class Period End	9/7/2018														
Acquisition Date	Quantity of Securities Purchased	Quantity of Securities Adjusted	Price Per Security	Price Per Security Adjusted	Total Cost	Disposition Date	Securities Sold	Actual Sales Price Per Security	Avg. Trading Price on Date of Sale*	Total Proceeds from Sale	Held at Close of Class Period	Per Security Value	Retained Value	Total Proceeds/Loss (LIFO)	Dura LIFO**
10/1/2013	80,000	2,666.67	\$0.5600	\$16.80	\$44,800.0000					\$0.0000	2,666.67	2.491	\$ 6,642.67	\$38,157.33	\$38,157.33
10/2/2013	20,000	666.67	\$0.5000	\$15.00	\$10,000.0000					\$0.0000	666.67	2.491	\$ 1,660.67	\$8,339.33	\$8,339.33
10/4/2013	8,000	266.67	\$0.4750	\$14.25	\$3,800.0000					\$0.0000	266.67	2.491	\$ 664.27	\$3,135.73	\$3,135.73
6/1/2017	10,000	333.33	\$0.2000	\$6.00	\$2,000.0000					\$0.0000	333.33	2.491	\$ 830.33	\$1,169.67	\$1,169.67
6/1/2017	1,800	60.00	\$0.2000	\$6.00	\$360.0000					\$0.0000	60.00	2.491	\$ 149.46	\$210.54	\$210.54
6/1/2017	5,200	173.33	\$0.1971	\$5.91	\$1,024.9200					\$0.0000	173.33	2.491	\$ 431.77	\$593.15	\$593.15
6/2/2017	1,000	33.33	\$0.2000	\$6.00	\$200.0000					\$0.0000	33.33	2.491	\$ 83.03	\$116.97	\$116.97
6/2/2017	4,000	133.33	\$0.2047	\$6.14	\$818.8000	1/29/2018***	0.33	\$16.9697		\$5.6000	133.00	2.491	\$ 331.31	\$481.89	\$481.89
<b>TOTAL:</b>	<b>130,000</b>	<b>4,333.33</b>			<b>\$63,003.72</b>		-			<b>\$5.60</b>	<b>4,333.00</b>		<b>\$ 10,793.51</b>	<b>\$52,204.61</b>	<b>\$52,204.61</b>

\* Post-class period sales valued using the greater of: (1) the average closing price between the end of the class period and the sales date; or (2) the actual sales price.

\*\* Disregarding intra-class period gains and losses.

\*\*\* Forced sale due to holding of fractional share.